MUTTA ADC Platform: Engineering Novel Dual Targeting ADCs With an Improved Therapeutic Window

• Introducing the multi-faceted MUTTA platform to develop multi-epitope targeting tetravalent ADCs
• Leveraging MUTTA platform to expand development of differentiated dual targeting ADCs, screening over 50 unique target pairs to identify >15 novel dual targeting MUTTA ADCs
• Presenting preclinical data on several programs including the dual targeting MUC16 and NaPi2b ADC (AV-P138-ADC/ ARR-002)

Speakers:

Jagath Junutula

Co-Founder & Chief Executive Officer

Aarvik Therapeutics